Approximately 2.3% of adults will suffer from symptoms of Obsessive-Compulsive Disorder at some point in their life.
Exploring the companies and themes that make up this emerging and exciting new sector
The First Psychedelic Medicine Clinic Opens in Minnesota
The growing rates of depression, anxiety, and other mental health illnesses have contributed to a national mental health crisis in the United States and call for new and unconventional treatment options.
Lobe Sciences Added to Horizons Psychedelic Stock Index ETF
Lobe Sciences becomes the latest addition to the Horizons psychedelics ETF (PSYK).
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Cybin inks a drug development agreement with Catalent, "the leading global provider" of drug delivery, development and manufacturing solutions.
COMPASS Pathways granted two US patents
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
Investing in Psychedelics with MindMed Stock
It was the late Robin Williams who once said, “Reality is just a crutch for people who can’t handle drugs.”
MindMed Announces Inclusion in FTSE Russell Indexes
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Psychedelic Drugs: The Miracle Drugs of the 21st Century
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
Andrew Yang Urges Legalization Of Psilocybin And Marijuana At New York City Mayoral Forum
Andrew Yang, a former 2020 Democratic presidential candidate who is now running for mayor of New York City, said in a recent campaign forum that he supports legalizing psilocybin and marijuana.
Top Psychedelic Penny Stocks To Watch After Latest Big Pharma Deal
Psychedelic Penny Stocks Continue Gaining Ground Among Mainstream Investors
Numinus Announces Closing of $40-Million Bought Deal Financing
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
How Analysts Are Asleep At The Wheel Regarding Psychedelic Stocks
Psychedelic drug stocks represent (by far) the best new opportunity in life sciences today. Institutional capital is flooding into the sector. But market analysts are asleep-at-the-wheel here.